Medify Solutions Limited (Pink Sheets MFYS) Explains the Sales Potential for UK Remote Access Market

Gateshead, England (ots/PRNewswire) - On the 1st September 2006,Medify Solutions Limited will roll out its 'remote access to patientnotes' product, MedifyRemote, to its National Health Service (NHS)customers. The first NHS site, as published previously , will be inDoncaster in the north of England.

This site is leading the way for the rest of the UK in terms ofdevelopment and user testing of the powerful Medify Remote liveproduct, which will bring many benefits for patients and users interms of greater efficiency and more accurate transfer ofinformation.

Operating through its N3 approved secure connection to the NHSpatient database; Medify will begin the roll out to its live NHScustomers. This will be coordinated through corporate partners whoare providing the patient record software and airtime connection tothe NHS.

The sales potential for Medify Remote is significant. For ease ofunderstanding, the product will be offered to the customer at amonthly charge in the region of US$85 per month. In the UK there areover 500 000 healthcare professionals, the primary target user. Thusthe market for Medify in the UK alone is US$510m per annum (85 x 500000 x 12).

Therefore for every 1% market penetration, the revenue for Medifyis $ 5.1m per annum.

Medify has the approved connection to NHS' N3, the secure nationalIT network and has contracts to provide the service to NHSHealthcare professionals, which will now roll out over the next 12months. As the only provider to offer the service Medify is set toachieve significant revenues starting on the 1st of September 2006.

Of further importance is that UK Healthcare professionalsrepresent approximately 10% of the overall European market andapproximately 1% of a total global market of 59 millionprofessionals (potential users).

Contact : press@medifysolutions.com

Company website : www.medifysolutions.com

This news release contains forward-looking statements that aresubject to certain risks and uncertainties that may cause actualresults to differ materially from those projected on the basis ofsuch forward-looking statements. The words "estimate," "project,""intends," "expects," " believes," and similar expressions areintended to identify forward-looking statements. Suchforward-looking statements are made based on management's beliefs,as well as assumptions made by, and information currently availableto, management pursuant to the "safe-harbour" provisions of thePrivate Securities Litigation Reform Act of 1995. For a more completedescription of these and other risk factors that may affect thefuture performance of Medify Solutions Limited, see "Risk Factors"in the Company's Annual Report on Form 10-KSB and its other filingswith the Securities and Exchange Commission. Readers are cautionednot to place undue reliance on these forward-looking statements,which speak only as of the date made and the Company undertakes noobligation to disclose any revision to these forward-lookingstatements to reflect events or circumstances after the date made orto reflect the occurrence of unanticipated events.

ots Originaltext: Medify Solutions Ltd.Im Internet recherchierbar: http://www.presseportal.de

Contact:For further information: Jonathan Bryant, Group Chairman, Medify Solutions, Tel: +44-(0)845-034-4090, Fax: +44-(0)1785-214474, jbryant@medifysolutions.com

Medify Solutions Ltd.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Medify Solutions Limited (Pink Sheets MFYS) Explains the Sales Potential for UK Remote Access Market